Interplay of protein misfolding pathway and unfolded-protein response in acute promyelocytic leukemia

Expert Review of Proteomics
Matiullah Khan

Abstract

Protein misfolding has traditionally been linked to the pathogenesis of various neurodegenerative diseases. However, emerging evidence from various laboratories, including ours, suggests that protein misfolding may also play a fundamental role in some malignancies, particularly those caused by fusion oncoprotein generated from chromosomal translocation. Promyelocytic leukemia (PML) fused to the retinoic acid receptor (RAR) is a fusion oncoprotein linked to the transformation of acute promyelocytic leukemia (APL), and is not only a misfolded protein itself, but also promotes misfolding of nuclear receptor corepressor (N-CoR) protein, a corepressor essential for the growth-suppressive function of several tumor-suppressor proteins. PML-RAR promotes misfolding of N-CoR by inducing aberrant post-translational modification, which destabilizes its core and promotes instability. Misfolded N-CoR, thus, contributes to differentiation arrest and survival of APL cells through loss-of-function and aberrant gain-of-function properties. Therapeutic restoration of N-CoR conformation and function with conformation-modifying agents not only releases this differentiation arrest but also sensitizes APL cells to programmed cell death. These finding...Continue Reading

References

Jul 23, 1996·Proceedings of the National Academy of Sciences of the United States of America·E EarlyE Dmitrovsky
May 13, 1997·Proceedings of the National Academy of Sciences of the United States of America·L Z HeP P Pandolfi
Oct 6, 1997·Proceedings of the National Academy of Sciences of the United States of America·P F FerrucciP G Pelicci
Jun 24, 1998·Proceedings of the National Academy of Sciences of the United States of America·N LehmingM Ptashne
Dec 28, 1999·Proceedings of the National Academy of Sciences of the United States of America·J ZhuH de Thé
Jan 29, 2000·The Journal of Cell Biology·F M BoisvertD P Bazett-Jones
Sep 5, 2001·The EMBO Journal·M ZyliczA Wawrzynow
Nov 13, 2001·Oncogene·L Degos, Z Y Wang
Jan 5, 2002·The New England Journal of Medicine·Robin W Carrell, David A Lomas
Oct 10, 2003·The Journal of Biological Chemistry·R Scott WilliamsJ N Mark Glover
Jan 1, 2004·The Journal of Biological Chemistry·Md Matiullah KhanShunsuke Ishii
Dec 2, 2004·Nature Reviews. Cancer·Yanjun Ma, Linda M Hendershot
Dec 17, 2004·Molecular and Cellular Biology·Andrew A Lane, Timothy J Ley
Oct 1, 2005·Proceedings of the National Academy of Sciences of the United States of America·Nora S GreenJeffery W Kelly
Nov 24, 2005·The FEBS Journal·Thomas R Jahn, Sheena E Radford
May 26, 2006·Annual Review of Genomics and Human Genetics·Niels GregersenJane H Christensen
Jan 30, 2007·Nature Reviews. Immunology·Frank Rosenbauer, Daniel G Tenen
Aug 19, 2007·Molecular Cancer Therapeutics·Angela Ping Ping NgMatiullah Khan
Jan 20, 2010·Nature Reviews. Genetics·Valentina PerissiMichael G Rosenfeld

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis